Who Is Suitable for GFC Therapy in Knee Osteoarthritis? A Patient Selection Guide

Knee osteoarthritis is not a single-stage condition, and no injection is appropriate simply because an X-ray shows arthritis. The more useful question is whether a blood-derived injection has a reasonable clinical objective for a particular patient at a particular stage of disease.

Growth Factor Concentrate (GFC) is prepared from a patient’s own blood using a system designed to activate platelets and collect a growth-factor-rich fraction. It is related to the broader family of platelet-derived treatments, but GFC should not automatically be treated as interchangeable with every platelet-rich plasma (PRP) preparation. Commercial systems differ in processing, cellular content and final product, and the GFC-specific evidence base remains substantially smaller than the PRP literature.

📝 In This Article

• Patient selection starts with the diagnosis

• Where GFC may reasonably fit

• What should not be promised

• Who may be less likely to benefit

• GFC vs PRP: The evidence should be explained honestly

• What about GFC-specific evidence?

• GFC should sit inside a complete knee-arthritis pathway

• Questions patients should ask before proceeding

• The practical principle

🦵 Patient Selection Starts With the Diagnosis, Not the Injection

Before discussing GFC, the clinician should confirm that osteoarthritis is actually the principal source of symptoms. Knee pain may also arise from patellofemoral disease, meniscal degeneration, tendinopathy, bursitis, inflammatory or crystal arthritis, referred pain from the hip or spine, and less commonly infection or other pathology.

For confirmed knee osteoarthritis, treatment selection should combine symptoms, examination, radiographs, alignment, functional limitation, previous treatment response, medical conditions and patient goals. Radiographic severity matters, but it should not be interpreted in isolation.

💉 Where GFC May Reasonably Fit

The most defensible role for GFC is as a selected symptom-modifying option in patients with early-to-moderate knee osteoarthritis who remain symptomatic despite an appropriate foundation of non-operative care.

A potentially suitable patient is more likely to have:

• confirmed symptomatic knee osteoarthritis rather than an uncertain diagnosis;

• mild-to-moderate structural disease rather than severe joint destruction;

• persistent pain or activity limitation despite appropriate exercise, activity modification, weight management when relevant and other suitable conservative measures;

• realistic expectations about the objective of treatment;

• no contraindication to an intra-articular procedure; and

• willingness to continue rehabilitation rather than viewing the injection as a substitute for strengthening and long-term joint care.

The intended outcome should usually be improvement in pain and function. Walking tolerance, stairs, sleep, use of rescue medication and ability to participate in exercise are more useful measures of response than vague claims that the joint has been “regenerated.”

🚫 What Should Not Be Promised

GFC should not be described as a stem-cell treatment, a guaranteed cartilage-regrowth procedure, a cure for osteoarthritis or a reliable method of reversing advanced structural disease. Symptom improvement does not prove that cartilage has regrown or that the natural history of arthritis has been permanently altered.

This distinction is important because regenerative terminology can easily create expectations that exceed the available clinical evidence.

⚠️ Who May Be Less Likely to Benefit?

An injection becomes less compelling when the central problem is advanced mechanical and structural disease. Patients with severe joint-space loss, major deformity, substantial instability, marked fixed stiffness or major functional limitation may obtain limited or temporary symptom relief while the underlying mechanical problem remains.

Likewise, repeated injections should not become a mechanism for indefinitely postponing a necessary surgical discussion. When pain and functional loss are substantial, appropriate non-operative treatment has failed, and imaging and examination are concordant, knee replacement may offer a more predictable treatment pathway.

The decision is not “injection versus surgery” in the abstract. It is whether continued conservative treatment still has a reasonable probability of achieving the patient’s goals.

🔬 GFC vs PRP: The Evidence Should Be Explained Honestly

PRP has a substantially larger clinical research base in knee osteoarthritis. However, PRP itself is heterogeneous: platelet concentration, leukocyte content, activation, red-cell contamination, injection volume and dosing schedules vary between preparations.

Recent professional guidance continues to reflect this nuance. The American Academy of Physical Medicine and Rehabilitation’s 2026 guidance recommends considering PRP for symptomatic mild-to-moderate knee osteoarthritis after conservative treatment, while emphasizing variability in preparations and the need for evidence-informed patient selection. Other major guidelines have reached different conclusions because they weigh heterogeneous preparations, study quality and effect sizes differently.

🧪 What About GFC-Specific Evidence?

GFC-specific research is more limited. Published reviews have highlighted the small number of eligible clinical studies and the need for larger multicentre randomized trials and direct comparisons. It is therefore not scientifically appropriate to claim that GFC is universally superior to PRP.

A more accurate discussion is that both are autologous blood-derived approaches, their final products differ according to preparation systems, PRP has the broader evidence base, and the choice should be made with explicit acknowledgement of what is known and what remains uncertain.

🏃 GFC Should Sit Inside a Complete Knee-Arthritis Pathway

Injection therapy should not displace interventions with strong roles in osteoarthritis management. Therapeutic exercise, strength training, activity modification, weight management when appropriate, education and selected analgesic or anti-inflammatory strategies remain important. Bracing, walking aids and physiotherapy supervision may also be useful for selected patients.

If an injection reduces symptoms enough to improve walking and participation in rehabilitation, that can be a clinically meaningful result. If symptoms remain severe despite appropriate treatment, repeating procedures without reconsidering the diagnosis and disease stage is difficult to justify.

❓ Questions Patients Should Ask Before Proceeding

Patients considering GFC or PRP should ask:

1. What is my exact diagnosis and arthritis stage?

2. Why is an injection reasonable in my case?

3. What preparation or system will be used?

4. Is the proposed protocol supported by evidence specific to that preparation, or mainly by broader PRP evidence?

5. What improvement should realistically be expected?

6. How will we decide whether the treatment has worked?

7. What are the risks, alternatives and costs?

8. What is the plan if there is little or no benefit?

9. At what point should knee replacement or another treatment be discussed?

🎯 The Practical Principle

GFC may be reasonable for selected patients with early-to-moderate knee osteoarthritis, but patient selection matters more than the treatment label. The objective is not to sell an injection or to avoid surgery at all costs. It is to match the least invasive treatment that has a reasonable evidence-based chance of meeting the patient’s goals, while recognizing when the disease has progressed beyond what an injection can realistically achieve.